1 / 4

Idiopathic pulmonary fibrosis market new business opportunities & investment research report 2027

Idiopathic pulmonary fibrosis (IPF) alternatively termed as the cryptogenic fibrosing alveolitis is the chronic and progressive fibrosing interstitial pneumonia affecting lungs. It results in scarring of the lungs ultimately reduces the oxygen intake. With progression, the functional ability of the pulmonary organ declines along with shortness in breath resulting in respiratory failure and ultimately to death. The exact cause of idiopathic pulmonary fibrosis (IPF) is still unknown. However, some risk factors include smoke, wood, dust, & gastroesophageal reflux. Despite chronic and fatal pulmonary disease, no cure treatment or drug is currently available, however, some of the therapies are efficient in reducing the progression of the lung scarring.

prithvi19
Download Presentation

Idiopathic pulmonary fibrosis market new business opportunities & investment research report 2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Idiopathic Pulmonary Fibrosis Market Size, Share, Investment Opportunities, Top Regions, Growth & Forecast by 2027 The Global Idiopathic Pulmonary Fibrosis Market is projected to reach a value of over USD 4.95 Million by 2027 at a CAGR of 12%. Idiopathic pulmonary fibrosis (IPF) alternatively termed as the cryptogenic fibrosing alveolitis is the chronic and progressive fibrosing interstitial pneumonia affecting lungs. It results in scarring of the lungs ultimately reduces the oxygen intake. With progression, the functional ability of the pulmonary organ declines along with shortness in breath resulting in respiratory failure and ultimately to death. The exact cause of idiopathic pulmonary fibrosis (IPF) is still unknown. However, some risk factors include smoke, wood, dust, & gastroesophageal reflux. Despite chronic and fatal pulmonary disease, no cure treatment or drug is currently available, however, some of the therapies are efficient in reducing the progression of the lung scarring. Get Sample Copy of This Report @ https://www.forencisresearch.com/idiopathic- pulmonary-fibrosis-market-sample-pdf/ idiopathic pulmonary fibrosis Market: Drivers & Challenges Market Driver: Growing Elderly Population The Idiopathic Pulmonary Fibrosis (IPF) market is expected to drive on the grounds of a rising count of the aged population across the world. The incidence of the fresh IPF cases is usually diagnosed and progressed in the aged population, whereas, the prevalence of the disease is usually low in the population ranging between 18 to 60 years. Studies have shown that the incidence of IPF among the young population ranges between 5-6 cases in 1,00,000 people annually, whereas, 11 cases in aged 1,00,000 people. World Population Prospects: the 2019 Revision by United Nations estimated that the aged population (over 65 years) will rise to 16% representing one in six people globally, uprise 9% equals to one in 11 in 2019. It further states that one in four Europe and Northern American population could be aged 65 or over by 2050. Owing to the rapidly rising aged population, which is more prone to IPF, drives the demand for IPF treatment.

  2. Increase in Smokers Population Globally, the rise in smokers population across the globe is projected to push the market growth higher. One of the prominent risk factor associated with the incidence of IPF is smoking. Also, the mortality rate of the IPF patient is associated with smoking tobacco. As per the Center of Disease Control and Prevention (CDC), over 16 million Americans are suffering from disease-related or caused by smoking. It further adds, around 14 of the 100 American adults smoked a cigarette in 2018. Also, the data shared by CDC reflects that every day, around 2000 people younger than 18 years starts smoking. The rising count of smokers across the globe is creating a higher possibility of causing IPF, which further promotes the demand for IPF treatment. Due to the aforementioned factor, the IPF market is experiencing growth at a rapid rate. Market Restraint: High Treatment Cost The cost associated with IPF treatment to the healthcare system lies around USD 2 billion for the aged population. Whereas the annual direct medical costs of the same treatment for the IPF patient within the USA is around two-fold higher i.e. USD 20, 887 vs USD 8,932, the basis of gender and age. The high cost of the drugs associated with idiopathic pulmonary fibrosis retards the patients from using or continue taking the drugs. Also, the increase in overall medical costs for both inpatient and outpatient services, hinder the adoption of the treatment by the patients. Owing to the high cost of the IPF treatment, the growth of this market is expected to impact negatively. Idiopathic pulmonary fibrosis Market: Key Segments Segmentation based on treatment: Pharmacological Therapies and Non- pharmacological Therapies Segmentation based on region covers: North America, Asia-Pacific, Europe, Middle East & Africa and South America, with individual country-level analysis. Request Report Methodology On Competition On Global Idiopathic Pulmonary Fibrosis Market Here @ https://www.forencisresearch.com/idiopathic-pulmonary-fibrosis-market- request-methodology/ List of the leading companies operating in the Idiopathic Pulmonary Fibrosis Market include:

  3. F. Hoffmann-La Roche Ltd (Company Description, Company Overview, Product Synopsis, Key Developments, SWOT Analysis) Boehringer Ingelheim International GmbH MediciNova, Inc. Bristol-Myers Squibb Company Liminal BioSciences Inc. Merck & Co., Inc. Galapagos NV Novartis AG FibroGen, Inc. Cipla Inc Other Key Companies Idiopathic pulmonary fibrosis Market: Report Segmentation For the scope of the report, In-depth segmentation is offered by Forencis Research Idiopathic Pulmonary Fibrosis Market, by Treatment Pharmacological Therapies o  oAnti-fibrotic Drugs Non-pharmacological Therapies o  oLung Transplant oCell-based Transplantation oOxygen Therapy To Understand How COVID-19 Impact is Covered in This Report. Consult with an Analyst @ https://www.forencisresearch.com/idiopathic-pulmonary-fibrosis-market-consult-with-an- analyst/ Idiopathic Pulmonary Fibrosis Market by Region

  4. Asia-Pacific (China, Japan, South Korea, India, Taiwan, Rest of Asia-Pacific) North America (US, Canada, Mexico) Europe (Germany, Russia, France, Italy, UK, Spain, The Netherlands, Rest of Europe) Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) South America (Brazil, Argentina, Rest of South America) Purchase this Premium Industry Research Report with Analysis @ https://www.forencisresearch.com/idiopathic-pulmonary-fibrosis-market-purchase-now/ About Forencis Research Forencis Research is a B2B market research, intelligence and advisory firm engaging in market research and consulting services across leading industries, globally. Our robust and meticulous research team provides high growth and niche syndicated reports, customized reports and consulting reports to the diverse global fortune clientele and intellectual institutions. Forencis Research database is a constantly evolving pool of reports and white paper studies which helps companies to foster accelerated revenue growth in global and regional markets. Forencis Research delivers market research and consulting reports on high growth markets to help companies dominate their competition and set themselves apart by attaining increased revenue growth. To enable exclusive insights around the target market, Forencis Research employs robust research Methodology & Design which includes data acquisition, data synthesis and data correlation, through Primary and Secondary Research. Through the obtained data, Top-down and bottom-up methods are exercised to attain and verify data sanity within the entire market. This market data is yet again correlated with Forencis Research’s internal database before presenting it in any of our final publications. These methods of data correlation and amalgamation benefit us to put forward accurate market estimates enabling our clients to transform their business, markets and most importantly their “REVENUES”. Contact Us FORENCIS RESEARCH Phone: +1 (720) 306 9020 Email:info@forencisresearch.com For more market research insights, please visit https://www.forencisresearch.com

More Related